Skip to main content

Table 2 Treatment with oxygen therapy and prone positioning (see also, Additional file 1: Table E2)

From: Impact of exposure time in awake prone positioning on clinical outcomes of patients with COVID-19-related acute respiratory failure treated with high-flow nasal oxygen: a multicenter cohort study

Oxygen therapy and prone positioning

Awake prone positioning

(n = 187)

Non-prone positioning

(n = 148)

Previous to ICU-admission O2 therapy, n (%)

 Low-flow O2 Cannula

69 (37)

47 (32)

 Venturi mask

8 (4)

5 (3)

 Non-rebreathing mask

110 (59)

96 (65)

HFNO therapy and body position (at ICU)

 Days on HFNO, median (p 25–75)

5 (3–7)

3 (1.5–7)

 Time of AW-PP (h/day), median (p 25–75)

12 (9–16)

0 (0–2)

 Time on AW-PP (days), median (p 25–75)

5 (3–8)

0 (0–1)

Basal setting of HFNO

 Flow (liters/min), median (p 25–75)

60 (60–60)

60 (60–60)

 FiO2, mean (SD)

0.6 (0.5–0.7)

0.6 (0.5–0.75)

HFNO at weaning

 FIow (liters/min), median (p 25–75)

40 (40–40)

40 (40–40)

 FiO2, median (p 25–75)

0.3 (0.3–0.4)

0.3 (0.3–0.4)

  1. AW-PP: awake prone position; FiO2: fraction of inspired oxygen; HFNO: O2 therapy with high-flow nasal cannula; ICU: intensive care unit